510(k) Report

510(k) · Cleared

Cleared

Doopang

K232749510(k) TraditionalCleared Jun 11, 2024277-day reviewClass II21 CFR 882.5891

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Ybrain, Inc. · PCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine

Cleared on Jun 11, 2024 as substantially equivalent to K201895 (Cefaly Technology, 2020) after a 277-day review. Its family tree reaches back 5 generations to 2014.

Decided
Jun 11, 2024
Review
277 days
Class
Class II
Product code
PCC
Recalls
None
Predicates
1

Its longest line of descent runs back 5 generations to DEN120019 (2014). No later device cites it as a predicate yet.

  1. Root · 5 generations backDEN120019 CefalyStx-Med Sprl · 2014
  2. 4 generations backK160237 CefalyCefaly Technology · 2016
  3. 3 generations backK171446 Cefaly AcuteCefaly Technology · 2017
  4. 2 generations backK173006 Cefaly DualCefaly Technology · 2017
  5. 1 generation backK201895 Cefaly DualCefaly Technology · 2020
  6. This deviceK232749 DoopangYbrain, Inc. · 2024
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−5DEN120019CefalyStx-Med Sprl2014—
−4K160237CefalyCefaly Technology2016—
−3K171446Cefaly AcuteCefaly Technology2017—
−2K173006Cefaly DualCefaly Technology2017—
−1K201895Cefaly DualCefaly Technology2020—
0 (this device)K232749DoopangYbrain, Inc.2024—
FIG. 1 — Lineage of K232749, 2014–2024Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PCC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PCC device

  1. #1 K201895 Cefaly Dualscore 16.0 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K201895Cefaly Dual
Summary page 6
…evice(s) [21 CFR 807.92(a)(3)] The identified predicate device within this submission is shown as follow; Predicate Device 510(k) Number K201895 Trade/Device/Model Name Cefaly Dual Transcutaneous Electrical Nerve Stimul…
Cefaly Technology2020—

Also cleared against K201895: 4 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 10 years and passes through 3 companies; a new generation was cleared every 2.0 years on median.
  • None of the 5 ancestors has a recall.
  • 4 other devices also cite its predicate K201895.

How does its category compare?

All PCC devices

PCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine: FDA decisions, review times, recalls and adverse event reports over 20 years. 2024, this device’s year, is highlighted.

FDA decisions per year · PCC

5in 2024

2014: 12016: 12017: 22018: 12019: 12020: 12021: 42022: 12024: 52026 (partial year): 1
2007high 5 (2024) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PCC

211in 2024

2021: 88 days median2024: 211 days median
2007high 211 (2024) · low 88 (2021)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · PCC

No recall names PCC since 2007.

Adverse event reports per year · PCC

2in 2025

2014: 22016: 22017: 22019: 22020: 12021: 72023: 22024: 62025: 2
2007high 7 (2021) · low 0 (2007)2025

MAUDE reports naming product code PCC, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20141—02
20150—00
20161—02
20172—02
20181—00
20191—02
20201—01
202148807
20221—00
20230—02
2024521106
20250—02
20261—0—

What is it indicated for?

The DOOPANG(YPS-301BD) is indicated for:

- The acute treatment of migraine with or without aura in patients 18 years of age or older.

- The prophylactic treatment of episodic migraine in patients 18 years of age or older.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K232749: Doopang.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K232749

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026